Future-proof your AAV process with a complete producer cell line – just induce and grow
Sponsor
Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Stable producer cell lines helped to make mAb therapies the powerhouses that they are today. To deliver on the promise of AAV-based gene therapy for prevalent diseases, similar technology is required. The challenge is that multiple genetic elements – rep, helper, capsid, and gene of interest (GOI) – must be present. Ideally, everything needed to produce the required rAAV would be stably integrated into a single cell line.
In this webinar, we describe an all-inclusive cell line platform that can be customized for your specific GOI and capsid. Just add the induction agent, and you’re ready to go.
- Discover the drawbacks of using an incomplete cell line
- See how to use the ELEVECTA™ platform to produce high-quality AAV at high yield for indications with large patient populations
- Take a deep dive into data on robust scaling to large-scale stirred tank bioreactors
- Learn how to optimize your upstream processing with cells, media, bioreactors, and filters that work in tandem
SPEAKERS
You might also like
Control your AAV titers with in-line UV-Vis analysis and PAT-Driven UF/DF systems
Improving AAV productivity and packaging efficiency for transient and producer cell lines through plasmid engineering
Accelerating AAV process development with PAT-driven TFF system
It’s a match: cell line engineering for AAV manufacturing expands the options for therapeutic programs
